Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Catalyst plans to use the net proceeds from the offering: (i) to continue the commercialization activities for Firdapse (amifampridine phosphate); (ii) to fund business expansion activities in the U.S. and
The offering will be made pursuant to a preliminary prospectus supplement to Catalyst's prospectus to be filed under Catalyst's effective
When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities will be available on the Investor Relations section of the Company's website and on the
Firdapse is currently being evaluated in clinical trials for the treatment of MuSK-MG, CMS, and SMA Type 3 and has received Orphan Drug Designation from the
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results and may include, without limitation, risks related to market conditions and other conditions related to the proposed offering. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2018 and its other filings with the
Brian KorbSolebury Trout (646) 378-2923 firstname.lastname@example.org Company Contact Patrick J. McEnany Catalyst PharmaceuticalsChief Executive Officer (305) 420-3200 email@example.com Media Contacts David Schull Russo Partners(212) 845-4271 firstname.lastname@example.org
Source: Catalyst Pharmaceuticals, Inc.